Work

Tolvaptan Modifies Patient Risk Class Distribution Over Time in Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Data From the TEMPO 3:4 Trial

Year: 2022

Type: article

Source: Journal of the American Society of Nephrology

DOI: 10.1681/asn.20223311s1161d

Authors: Neera K. Dahl, Fouad T. Chebib, Frederic F. Rahbari-Oskoui, Hina Japes, Huan Jiang, LaRee A. Tracy, Linda Mccormick, Katherine Maringer, Ronald D. Perrone, Ali Nourbakhsh

Institutions: Yale University, Mayo Clinic, Emory University, Otsuka (United States), Otsuka Pharmaceutical Development & Commercialization, Inc. (United States), Tufts Medical Center

Language: English

Topic: Genetic and Kidney Cyst Diseases

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4396989978

FWCI: 0.135

Cites:

Cited by: 1

Related to: 10